New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
Stocks closed sharply lower after being down all day on Fed Chairman Ben Bernanke's remarks that "economic uncertainty" has increased. "The market has these little flips up and down but it's been quiet and down all day long," said Mike Driscoll, head of listed trading at Bear Stearns
Stocks closed lower after a new warning from the housing industry kept buyers out of the market. "Even though we may test the lows just because some short-term investors may get out of the way, this market has been really good shape," said Richard Steinberg, president and chief investment officer at Steinberg Global Asset Management. "If we pull back, investors should be reassessing their portfolios and looking to pick up bargains."
Plaintiff Frank Schwaller sued Merck after his wife, Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003.
Stocks ended mixed as the major markets bounced off the day's lows following disappointing monthly housing data. "We may see some weakness, but overall we like the market. I think the direction is going to be higher," said Sebastian Leburn, chief investment officer at Weiss Capital Management, in an interview with CNBC.com.
Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.
U.S. drugs giant Abbott Laboratories said it would stop launching new medicines in Thailand in protest at the army-backed government's move to override international drug patents.
The chief executive of Merck received compensation the company valued at $8.04 million last year, according to a regulatory filing Monday.
Painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and hitting drugmaker Merck with a total of $47.5 million in damages.
Stocks closed higher as investors overcame concerns about subprime lending to spark a late-day rally. "We're going through a short-term bounce," Mark Arbeter, Chief Technical Strategist at Standard & Poor's, told CNBC. "Volume, so far, on the upside has been fairly light, which is not encouraging. "
A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.
Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....
It's time to step back from the madness and understand a basic tenet of the markets: Just because something negative happens somewhere, it doesn't mean the sky is falling. In fact, it could be good news for you. Here's why...
On February 26th, Guy Adami, The Negotiator recommended this drug play. "Mylan Labs, you've gotta go the generic route… I'm going the generic route…I like Mylan Labs here. They had a nice earnings release I think this is a stock you have to own” Well guess what...
A New Jersey jury found on Friday that Merck failed to provide adequate warnings about health risks tied to its withdrawn arthritis drug Vioxx in one case, but decided that it gave adequate warning in another in two suits tried simultaneously.
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
Stocks finished the day higher after the Fed chairman reassured investors that the economic outlook is not changed. "The (markets) valuation, if anything, has gotten a little bit better," Goldman, Sachs chief U.S. investment strategist Abby Joseph Cohen said. "Going forward, what matters is that the global economy still looks good."
One in four U.S. women ages 14 to 59 is infected with the sexually transmitted virus that in some forms can cause cervical cancer, according to the first broad national estimate.
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Stocks closed lower on concerns about economic growth and a rise in crude oil to its highest levels of the year. "Even with the corrective action we've seen since last week, consolidation is occurring in an orderly manner and that's positive," Gene Peroni, Senior Managing Director of Equity Research at Claymore Advisors, told CNBC.com.
Merck's stock rose before the opening bell Monday after U.S. regulators asked for more data on rival Novartis' diabetes drug, which gives Merck a leg up in the race to launch a new class of diabetes drugs.